share_log

HC Wainwright & Co. Reiterates Neutral on Eliem Therapeutics, Maintains $6 Price Target

Benzinga ·  Mar 8, 2023 06:23

HC Wainwright & Co. analyst Douglas Tsao reiterates Eliem Therapeutics (NASDAQ:ELYM) with a Neutral and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment